In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.
AUTOR(ES)
Bodey, G P
RESUMO
BMY-28142 was compared with other broad-spectrum antibiotics against gram-positive cocci and gram-negative bacilli. BMY-28142 was highly active against all gram-negative bacilli and especially against Enterobacter cloacae, Serratia marcescens, and Morganella morganii. Its in vitro activity suggests that BMY-28142 should prove to be useful for the treatment of gram-negative bacillary infections.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=176251Documentos Relacionados
- Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.
- In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.
- Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.
- Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporin.
- In vitro studies on the antibacterial activities of YM-13115, a new broad-spectrum cephalosporin.
